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ABSTRACT:
Metastasis suppressor 1 (MTSS1) is an important tumor suppressor protein, 
and loss of MTSS1 expression has been observed in several types of human cancers. 
Importantly, decreased MTSS1 expression is associated with more aggressive forms of 
breast and prostate cancers, and with poor survival rate. Currently, it remains unclear 
how MTSS1 is regulated in cancer cells, and whether reduced MTSS1 expression 
contributes to elevated cancer cell proliferation and migration. Here we report that 
the SCFβ-TRCP regulates MTSS1 protein stability by targeting it for ubiquitination and 
subsequent destruction via the 26S proteasome. Notably, depletion of either Cullin 1 
or β-TRCP1 led to increased levels of MTSS1. We further demonstrated a crucial role 
for Ser322 in the DSGXXS degron of MTSS1 in governing SCFβ-TRCP-mediated MTSS1 
degradation. Mechanistically, we defined that Casein Kinase Iδ (CKIδ) phosphorylates 
Ser322 to trigger MTSS1’s interaction with β-TRCP for subsequent ubiquitination 
and degradation. Importantly, introducing wild-type MTSS1 or a non-degradable 
MTSS1 (S322A) into breast or prostate cancer cells with low MTSS1 expression 
significantly inhibited cellular proliferation and migration. Moreover, S322A-MTSS1 
exhibited stronger effects in inhibiting cell proliferation and migration when compared 
to ectopic expression of wild-type MTSS1. Therefore, our study provides a novel 
molecular mechanism for the negative regulation of MTSS1 by β-TRCP in cancer cells. 
It further suggests that preventing MTSS1 degradation could be a possible novel 
strategy for clinical treatment of more aggressive breast and prostate cancers.  
INTRODUCTION
Tumor metastasis is a major problem encountered 
during clinical anti-cancer treatments, which causes 
higher mortality in cancer patients [1]. Therefore, 
elucidating the underlying molecular mechanisms that 
cause tumor growth and metastasis will lead to the 
development of more effective therapies, in part by 
eradicating metastatic cancer cells. To this end, it has 
been established that for many types of human cancers, 
tumor cells could acquire the capability to metastasize 
to distant organs that ultimately results in organ failure 
and death [1, 2]. Although the mechanisms remain largely 
unknown, overexpression of certain oncoproteins [3] or 
downregulation of tumor suppressor proteins [4] have 
been demonstrated to play important roles in the process 
of tumor growth and metastasis. In this regard, the 
metastasis suppressor 1 (MTSS1) protein, which is also 
known as MIM (missing in metastasis) has been recently 
characterized as a tumor suppressor protein [5]. Notably, 
MTSS1 is mostly expressed in normal tissues and in some 
non-metastatic cancer cell lines, however its expression 
is  significantly  decreased  or  mostly  absent  in  many 
metastatic cancers including metastatic bladder cancer [6], 
prostate cancer [7], gastric cancer [8]  and kidney cancer 
[9], suggesting that MTSS1 could function as an anti-
metastatic protein. Furthermore, an inverse correlation 
was also observed between MTSS1 expression and poor 
prognosis in breast cancer [10]. Specifically, findings from 
large cohort breast cancer clinical samples indicated that Oncotarget 2013; 4: 2340 www.impactjournals.com/oncotarget
decreased MTSS1 expression was positively associated 
with poorer prognosis, whereas high levels of MTSS1 
correlated with an increased overall patient survival [10]. 
Interestingly, it was reported that all three MTSS1 splice 
variants were significantly reduced in prostate cancer, 
whereas overexpression of MTSS1 markedly reduced the 
proliferation of prostate cancer cells [7]. These findings 
indicate that MTSS1 might function as a tumor suppressor, 
and loss of MTSS1 facilitates the development of human 
cancers including breast and prostate cancers. However, in 
contrast to its reduced expression in many human cancers, 
overexpression of MTSS1 was observed in hepatocellular 
carcinoma [11] although its physiological significance to 
liver cancer remains elusive.   
Functionally, MTSS1 acts as a cytoskeletal scaffold 
protein that regulates cytoskeletal dynamics through 
interacting with many different proteins such as Rac, 
actin and actin associated proteins [12-14]. By doing 
so, MTSS1 increases the formation of lamellipodia, 
membrane  ruffles,  and  filopodia-like  structures  and  is 
also involved in promoting the disassembly of actin stress 
fibers. Mechanistically, MTSS1 contains a WH2 domain 
in its C-terminal region that preferentially interacts with 
ATP-bound G-actin, an active form of actin involved 
in polymerization. Furthermore, it has been observed 
that MTSS1 possesses five-folds more affinity towards 
ATP-bound G-actin compared to ADP-bound G-actin 
associated with actin monomers in the cell. Recent studies 
have also suggested that MTSS1 competes with the WH2 
domain-containing neuronal Wiskott–Aldrich Syndrome 
protein (N-WASP) VCA protein for binding with G-actin 
[15]. Given the critical role of N-WASP in actin modeling 
and cytoskeleton formation [16], these findings reveal 
a critical role for MTSS1 in G-actin polymerization in 
part by inhibiting the physiological interaction between 
N-WASP and G-actin. In addition to interacting directly 
with G-actin, MTSS1 is also reported to interact with 
various other proteins such as the Rac GTPase, Cortactin 
and RPTPδ, all of which have been well-characterized as 
critical regulators of cell migration, invasion and cell-cell 
interaction [14, 16, 17]. Therefore, MTSS1 might govern 
various cellular processes including cellular migration or 
invasion in part by influencing cellular cytoskeleton. To 
this end, previous studies have also indicated that MTSS1 
could promote the formation of dorsal ruffels in response 
to PDGF to result in cell shape changes. Interestingly, 
PDGF induces phosphorylation of MTSS1 at Tyr-397 and 
Tyr-398 in a Src kinase-dependent manner [18]. These 
findings indicated that MTSS1 is potentially involved in 
mediating the PDGF signaling pathway to promote actin 
cytoskeleton formation via the Src-related kinases [18]. 
However, it remains largely unclear how MTSS1 stability 
is physiologicaly controlled, and which upstream signaling 
pathway aberrantly activated in cancer cells, contributes 
to the reduced MTSS1 abundance frequently observed in 
various human cancers.
The ubiquitin proteasome system (UPS) plays an 
important role in the timely regulation of key cellular 
proteins and thereby controlling many cellular processes 
including cell signaling and cell cycle regulation [19]. 
Dysfunction of the UPS is involved in the development of 
many diseases including cancer [20, 21]. Three enzymes 
are involved in protein ubiquitination and destruction 
process, the ubiquitin-activating enzyme (E1), the 
ubiquitin-conjugating enzyme (E2) and the ubiquitin 
ligase (E3), respectively and the E3 ligases determine 
the substrate specificity of the three-step ubiquitination 
process [19]. The SCFβ-TRCP E3 ubiquitin ligase complex 
plays a key role in cell cycle regulation [19]. However, 
its exact role as a tumor suppressor or oncogene might 
be tissue- or cellular context-dependent as both loss of 
β-TRCP, and aberrant upregulation of β-TRCP, have been 
reported in different types of human cancers [22]. Notably, 
elevated levels of β-TRCP were observed in a number of 
cancers including pancreatic cancer [23], gastric cancer 
[24] and breast cancer [25]. Furthermore, consistent 
with a possible oncogenic role for β-TRCP in certain 
tissues, another study demonstrated that suppression of 
β-TRCP  reduces  prostate  cancer  [26].  These  findings 
indicate that in certain tissue types, increased expression 
of β-TRCP may potentially lead to enhanced degradation 
of its substrates including possible tumor suppressors to 
facilitate tumorigenesis. In keeping with this notion, we 
report here that the tumor suppressor MTSS1 is a novel 
substrate of β-TRCP. In further support of our hypothesis, 
we have identified an evolutionally conserved phospho-
degron (DSGXXS) in MTSS1 that mediates the interaction 
with, and subsequent ubiquitination by β-TRCP in a CKI-
dependent manner. More importantly, ectopic expression 
of a non-degradable MTSS1 exerts stronger effects than 
WT-MTSS1  in  suppressing  tumor  cell  proliferation 
and migration. Therefore, these studies reveal the CKI/ 
β-TRCP signaling axis as the novel regulatory route to 
govern the stability of the MTSS1 tumor suppressor 
and  that  elevated  CKI  or  β-TRCP  expression  might 
lead to accelerated destruction of MTSS1 to facilitate 
tumorigenesis and tumor metastasis.
RESULTS
MTSS1 stability is negatively regulated by the 
SCFβ-TRCP E3 ubiquitin ligase complex:
Cullin–RING  complexes  comprise  the  largest 
known class of E3 ubiquitin ligases, which play essential 
roles in targeting regulatory proteins for ubiquitin-
mediated destruction [27]. Cullins are the critical scaffold 
proteins that complex with other essential components 
such as Skp1, F-box protein and Rbx1 to form various 
functional E3 ubiquitin ligases. Thus, we began our Oncotarget 2013; 4: 2341 www.impactjournals.com/oncotarget
investigation by examining whether a specific Cullin–
RING complex interacts with MTSS1. Notably, we found 
that Cullin 1 specifically binds with endogenous as well as 
ectopically expressed MTSS1, but not with other members 
of the Cullin family (Cullin 2-5) we examined (Figure 1A 
and Supplementary Figure S1A). This result suggests that 
the SCF complex (Skp1-Cullin1-F-box protein complex), 
might be specifically involved in the regulation of MTSS1 
protein stability. Next, we conducted studies to identify the 
specific F-box protein that regulate MTSS1 stability. To 
this end, previous studies from various groups including 
us showed that β-TRCP specifically binds with substrates 
that contain specific DSG(XX)S phosphodegron motif(s), 
in which the two serine residues are phosphorylated 
by one or more upstream kinases [28-30]. Notably, a 
DSG(XX)S phosphodegron motif was readily spotted 
within the MTSS1 protein, which was found to be 
conserved among various species (Figure 4A). To test 
the hypothesis that MTSS1 is a novel substrate of SCFβ-
TRCP,  we  examined  whether  β-TRCP  directly  interacts 
with MTSS1. We found that both exogenously expressed 
β-TRCP1 as well as endogenous β-TRCP1 interacts with 
MTSS1 (Figure 1B, 1C and Supplementary Figure S1B, 
S1C).  Furthermore,  β-TRCP1-R474A,  which  contains 
a mutation in its substrate-interacting motif [31], was 
deficient in associating with MTSS1, suggesting a specific 
interaction between β-TRCP1 and MTSS1 (Figure 1B 
and Supplementary Figure S1B, S1C). Importantly, we 
observed that phosphatase treatment significantly reduced 
the interaction between MTSS1 and β-TRCP1 (Figure 
1D), supporting a phosphorylation-dependent interaction 
between MTSS1 and β-TRCP1. 
Figure 1: SCF complex containing β-TRCP1 and Cullin 1 interacts with MTSS1. (A) Immunoblot (IB) analysis of whole cell 
lysates (WCL) and immunoprecipitates (IP) derived from 293T cells transfected with Myc-tagged Cullin constructs or empty vector (EV) 
as a negative control. (B) IB analysis of WCL and IP derived from 293T cells transfected with Flag–tagged wild-type or R474A mutant 
β-TRCP1 constructs, or EV as indicated. (C) 293T cell extracts were immunoprecipitated with antibody against MTSS1, or control IgG 
and analyzed by IB analysis. (D) IB analysis of WCL and IP derived from 293T cells transfected with Myc-MTSS1 and Flag–β-TRCP1 
constructs as indicated. Where indicated, cell lysates were pre-treated with λ-phosphatase before the IP procedure. (E) IB analysis of WCL 
and IP derived from 293T cells transfected with Myc-MTSS1 and Flag-Rbx1 constructs, as indicated. (F) IB analysis of WCL and IP 
derived from 293T cells transfected with GST-MTSS1 and Myc-Skp1 constructs, as indicated.Oncotarget 2013; 4: 2342 www.impactjournals.com/oncotarget
Consistent with the key role of the SCF complex 
in the regulation of MTSS1 stability, we also found 
interactions between MTSS1 and Rbx1 (Figure 1E and 
Supplementary Figure S1D) as well as between MTSS1 
and Skp1 (Figure 1F). These findings together suggest that 
the SCF complex comprising of Cullin 1, Rbx1, Skp1, and 
β-TRCP is involved in the regulation of MTSS1 stability. 
In further support of the physiological roles of β-TRCP 
and Cullin 1 in the regulation of MTSS1, we found that 
depletion of endogenous β-TRCP or Cullin 1 significantly 
upregulated MTSS1 (Figure 2A, 2B and Supplementary 
Figure  S2A,  S2B).  Importantly,  depletion  of  β-TRCP 
caused a marked increase in MTSS1 half-life (Figure 2C 
and 2D), but not in MTSS1 mRNA levels (Figure 2E and 
2F). Moreover, in support of the notion that SCFβ-TRCP 
might regulate MTSS1 abundance in a post-translational 
mechanism, treatment with the proteasome inhibitor, 
MG132, significantly upregulated MTSS1 protein levels, 
Figure 2: MTSS1 protein stability is controlled by the SCFβ-TRCP E3 ubiquitin ligase. (A) Immunoblot (IB) analysis of whole 
cell lysates (WCL) derived from 293T cells infected with shRNA constructs specific for GFP, β-TRCP1 (four independent lentiviral 
β-TRCP1-targeting shRNA constructs namely, -A, -B, -C, -D), or β-TRCP1+2, followed by selection with 1 µg/ml puromycin for three 
days to eliminate the non-infected cells. B) IB analysis of WCL from 293T cells transfected with shRNA specific for GFP, or several 
shRNA constructs against Cullin 1 (five independent lentiviral Cullin 1-targeting shRNA constructs namely, -A, -B, -C, -D, -E) followed by 
selection with 1 µg/ml puromycin for three days to eliminate the non-infected cells. (C) 293T cells were infected with the indicated shRNA 
constructs followed by selection with 1 µg/ml puromycin for three days to eliminate the non-infected cells. The generated stable cell lines 
were then split into 60-mm dishes. 20 hours later, cells were treated with 20 μg/ml CHX. At the indicated time points, WCL were prepared, 
and immunoblots were probed with the indicated antibodies. (D) Quantification of the band intensities in C. MTSS1 band intensity was 
normalized to tubulin, and then normalized to the t = 0 controls. The error bars represent mean ± SD (n = 3). (E-F) Relative mRNA levels 
of MTSS1 (E) or β-TRCP1 (F) in 293T cells infected with shRNA constructs specific for GFP, β-TRCP1 (-A and -B) or β-TRCP1+2 
followed by selection with 1 µg/ml puromycin for three days to eliminate the non-infected cells. MTSS1 and β-TRCP1 mRNA levels were 
normalized to GAPDH, and then normalized to the control cells (shGFP). (G) IB analysis of WCL derived from 293T cells treated with 
vehicle or MG132 as indicated.Oncotarget 2013; 4: 2343 www.impactjournals.com/oncotarget
indicating the potential involvement of 26S proteasome in 
MTSS1 degradation (Figure 2G). These findings together 
suggest that a post-transcriptional regulatory mechanism 
such as the ubiquitin proteasome system may be involved 
in the regulation of MTSS1 stability.
Figure 3: CKIδ is involved in the regulation of MTSS1 protein stability mediated by SCFβ-TRCP. (A) Immunoblot (IB) 
analysis of whole cell lysates (WCL) derived from HeLa cells transfected with Myc-MTSS1, Flag-β-TRCP1, and indicated kinases. Where 
indicated, cells were treated with the proteasome inhibitor MG132. (B) IB analysis of WCL derived from 293T cells transfected with Myc-
MTSS1 and/or Myc-CKIδ together with Flag-WT–β-TRCP1 or Flag-R474A–β-TRCP1. (C) IB analysis of WCL and immunoprecipitates 
(IP) derived from 293T cells transfected with GST-MTSS1 and Myc-tagged versions of the indicated CKI isoforms. (D) IB analysis of 
HeLa cells that were infected with shRNA specific for GFP or the indicated CKI isoforms, followed by selection with 1 µg/ml puromycin 
for three days to eliminate the non-infected cells. (E) IB analysis of HeLa cells treated with the CKI inhibitor D4476 at the indicated 
concentrations for 12 hours. (F) IB analysis of WCL and IP derived from HeLa cells that were infected with shGFP, shCKIδ-A or shCKIδ-B, 
followed by selection with 1 µg/ml puromycin for three days to eliminate the non-infected cells. The various generated HeLa cell lines were 
then transfected with Flag–β-TRCP1 and/or Myc-MTSS1 as indicated. (G) HeLa cells were infected with the indicated shRNA constructs 
followed by selection with 1 µg/ml puromycin for three days to eliminate the non-infected cells. The various generated HeLa cell lines were 
then transfected with Myc-MTSS1, Flag–β-TRCP1. 20 hours post-transfection, the cells were split into 60-mm dishes before being treated 
with 20 μg/ml CHX. At the indicated time points, WCL were prepared, and immunoblots were probed with the indicated antibodies. (H) 
Quantification of the band intensities in G. Myc-MTSS1 band intensity was normalized to tubulin, and then normalized to the t = 0 controls. 
The error bars represent mean ± SD (n = 3). Oncotarget 2013; 4: 2344 www.impactjournals.com/oncotarget
Casein  Kinase  Iδ  (CKIδ)  is  involved  in  the 
regulation of MTSS1 protein stability:
As  β-TRCP  only  recognizes  its  substrates  when 
they are properly phosphorylated by one or a combination 
of kinase(s) [32, 33], we sought to identify the upstream 
kinase that phosphorylates MTSS1 to trigger its 
destruction by β-TRCP. In this regard, both CKIδ and 
GSK3β have been previously identified as critical players 
in phosphorylating the targeted proteins of β-TRCP for 
ubiquitin-mediated protein degradation [34, 35]. Hence, to 
determine the specific kinase involved in the degradation 
of MTSS1, we transfected HeLa and 293T cells with 
Myc-MTSS1  and  Flag-β-TRCP1  along  with  CKIδ  or 
GSK3β and further analyzed MTSS1 levels by western 
blot analysis. Interestingly, we found that CKIδ, but not 
GSK3β, efficiently promoted the degradation of MTSS1 
(Figure 3A and Supplementary Figure S3A). Furthermore, 
MG132, a 26S proteasome inhibitor, completely prevented 
MTSS1 degradation mediated by CKIδ and β-TRCP1, 
suggesting the involvement of the 26S proteasome in 
this process (Figure 3A and Supplementary Figure S3A).   
Importantly,  the  mutant  β-TRCP1  (R474A),  which  is 
unable to interact with MTSS1 (Figure 1B), failed to 
promote MTSS1 degradation in the presence of CKIδ 
(Figure 3B and Supplementary Figure S3B), indicating 
a critical role for the C-terminal substrate-binding WD40 
repeat motif in β-TRCP1-mediated destruction of MTSS1. 
To further confirm the potential role of CKIδ in 
MTSS1 regulation, we utilized co-immunoprecipitation 
(Co-IP)  experiments  using  various  Myc-tagged  CKI 
isoforms and GST-MTSS1 to determine whether CKIδ 
directly interacts with MTSS1 in vivo. Notably, we found 
that CKIδ, but not other CKI isoforms such as CKIα or 
CKIε, specifically interacts with MTSS1 (Figure 3C). In 
further support a physiological role for CKIδ in governing 
MTSS1 stability, we demonstrated that MTSS1 abundance 
was significantly elevated upon inactivation of CKIδ by 
either depletion of endogenous CKIδ or by using a CKI 
inhibitor, D4476 (Figure 3D, 3E and Supplementary 
Figure S3C). More importantly, either depletion of 
CKIδ  (Figure  3F)  or  inactivation  of  CKIδ  by  D4476 
(Supplementary Figure S3D), significantly disrupted the 
interaction  between  β-TRCP  and  MTSS1.  In  keeping 
with the critical role of CKIδ in MTSS1 stability control, 
Figure 4: CKIδ-mediated phosphorylation of MTSS1 at Ser322 triggers its interaction with β-TRCP1 for subsequent 
ubiquitination and degradation. (A) Alignment of the candidate phospho-degron sequence in MTSS1 from different species. (B) 
Immunoblot (IB) analysis of HeLa cells transfected with Flag-β-TRCP1 and Myc-tagged wild-type or S322A mutant MTSS1 constructs, 
as indicated. (C) IB analysis of whole cell lysates (WCL) and immunoprecipitates (IP) derived from HeLa cells transfected with Flag–β-
TRCP1 together with Myc-WT–MTSS1 or Myc-S322A-MTSS1. (D) IB analysis of WCL and IP derived from 293T cells transfected with 
Flag-β-TRCP1, His-Ubiquitin, and Myc-tagged wild-type or S322A mutant MTSS1 constructs, or EV, as indicated.Oncotarget 2013; 4: 2345 www.impactjournals.com/oncotarget
depletion  of  CKIδ  significantly  extended  the  MTSS1 
protein  half-life  (Figure  3G  and  3H).  These  findings 
coherently indicated a potential role of CKIδ in negative 
regulation of the MTSS1 stability.
CKIδ phosphorylates Ser322 to promote MTSS1’s 
interaction  with  β-TRCP1  for  subsequent 
ubiquitination and degradation:
In  keeping  with  previously  identified  β-TRCP 
substrates, there is a canonical DSGXXS phospho-degron 
present in MTSS1 that could be recognized by β-TRCP 
upon proper phosphorylation by kinases [28]. Importantly, 
this degron is conserved among various species (Figure 
4A). To test the significance of this putative DSGXXS 
phosphodegron in MTSS1 protein stability, we created a 
point mutation in the DSG motif by replacing the Ser322 
residue with alanine (S322A). In support of the critical role 
for Ser322 in β-TRCP1-mediated destruction of MTSS1, 
we found that wild-type, but not the S322A mutant form 
of MTSS1, could be efficiently degraded in the presence 
of  β-TRCP1  and  CKIδ  (Figure  4B).  Moreover,  the 
proteasome inhibitor MG132 completely prevented the 
degradation of MTSS1 suggesting the involvement of 
a proteasome-mediated degradation mechanism in this 
process (Figure 4B). In keeping with this finding, unlike 
WT-MTSS1, S322A-MTSS1 was deficient in interacting 
with  β-TRCP1  (Figure  4C),  providing  a  possible 
explanation for its resistance to β-TRCP1/CKIδ-mediated 
destruction. Consistently, in vivo ubiquitination assays 
revealed that wild-type, but not the S322A mutant form of 
MTSS1, could be ubiquitinated in vivo (Figure 4D). These 
findings indicated that phosphorylation of Ser322 within 
the canonical phospho-DSG degron motif in MTSS1 is 
potentially involved in governing MTSS1 destruction 
mediated by β-TRCP and CKIδ.
β-TRCP-mediated destruction of MTSS1 affects 
cancer cell proliferation and migration:
Given  that  a  significant  decrease  in  MTSS1 
abundance is frequently observed in both prostate and 
breast cancers [7, 10], we sought to investigate whether 
MTSS1 expression in these cancer cells inversely 
correlates with cellular proliferation and migration. 
To begin this investigation, we first analyzed MTSS1 
protein levels in various prostate and breast cancer cell 
lines.  Notably, we found that the PC3 prostate cancer 
cells and the MDA-MB-231 breast cancer cells displayed 
a significantly reduced expression of MTSS1, whereas 
Figure 5: β-TRCP levels inversely correlate with MTSS1 abundance in several cancer cell lines. (A) Whole cell lysates 
(WCL) prepared from the indicated cancer cell lines were analyzed by immunoblot (IB) analysis. (B) IB analysis of WCL prepared from 
PC3 cells that were infected with shRNA constructs specific for GFP or Cullin 1, followed by selection with 1 µg/ml puromycin for three 
days to eliminate the non-infected cells. (C) IB analysis of WCL prepared from PC3 cells that were infected with shRNA constructs specific 
for GFP, β-TRCP1 (A, B), or β-TRCP1+2, followed by selection with 1 µg/ml puromycin for three days to eliminate the non-infected 
cells. (D) IB analysis of WCL prepared from MDA-MB-231 cells that were infected with shRNA constructs specific for GFP or Cullin 1, 
followed by selection with 1 µg/ml puromycin for three days to eliminate the non-infected cells. (E) IB analysis of WCL prepared from 
MDA-MB-231 cells that were infected with shRNA constructs specific for GFP, β-TRCP1 (A, B), or β-TRCP1+2, followed by selection 
with 1 µg/ml puromycin for three days to eliminate the non-infected cells.Oncotarget 2013; 4: 2346 www.impactjournals.com/oncotarget
DU145 and MCF-7 cells expressed relatively high MTSS1 
levels (Figure 5A). Furthermore, we noticed that the 
MTSS1 levels inversely correlate with the endogenous 
β-TRCP1  levels,  arguing  that  β-TRCP1  expression 
levels might dictate the abundance of MTSS1 in this 
experimental setting. To further examine this hypothesis, 
we depleted endogenous Cullin 1 or β-TRCP via lentiviral 
shRNA infection to examine its effects on MTSS1 
abundance. In keeping with a critical role for SCFβ-TRCP 
in governing MTSS1 stability, we found that depletion of 
either Cullin 1 or both β-TRCP isoforms led to a signficant 
upregulation of MTSS1 in both PC3 and MDA-MB-231 
cells (Figure 5 B-E).  
These results indicated that the SCF complex 
consisting of Cullin 1 and β-TRCP might play a key role 
in the regulation of MTSS1 in both breast and prostate 
cancer cells. As β-TRCP is the first identified E3 ligase 
for MTSS1, to explore the biological significance for 
Figure 6: Mutant MTSS1 inhibits PC3 and MDA-MB-231 cancer cell proliferation. (A-D) PC3 (A, B) or MDA-MB-231 
(C, D) cells were infected with pBabe-EV, pBabe-HA-wild-type-MTSS1 or pBabe-HA-S322A-MTSS1 retroviral vectors and photographs 
were taken after growing the generated stable cell lines for 3 days in puromycin (1 µg/ml) selection medium. The numbers of PC3 (B) 
or MDA-MB-231 (D) cells were quantified at the indicated time points. The number of cells was normalized against the number of cells 
in the corresponding pBabe-EV cells. The error bars represent mean ± SD (n = 3). (E-H) PC3 (E, F) or MDA-MB-231 (G, H) cells were 
infected with pBabe-EV, pBabe-HA-wild-type-MTSS1 or pBabe-HA-S322A-MTSS1 retroviral vectors and photographs were taken after 
growing the cells for 3 days in puromycin (1 µg/ml) selection medium to eliminate the non-infected cells. Furthermore, the generated cell 
lines were subjected to pulse of BrdU and then immunostained using anti-BrdU antibody as described in the methods section. Quantitative 
measurements of PC3 (F) or MDA-MB-231 (H) cells stained for BrdU were presented. The number of cells was normalized against the 
number of cells in the corresponding pBabe-EV cells. The error bars represent mean ± SD (n = 3) * p< 0.05.Oncotarget 2013; 4: 2347 www.impactjournals.com/oncotarget
SCFβ-TRCP-mediated destruction of MTSS1, next we 
intended to examine how ectopic expression of a non-
degradable mutant form of MTSS1 (S322A-MTSS1) or 
wild-type MTSS1 (as a control) in both PC3 and MDA-
MB-231 cancer cells could affect cellular migration or 
proliferation (Supplementary Figure S4A-B). Empty 
vector (EV) expressing cells were also used as a negative 
control for this experimental system. Importantly, 
S322A-MTSS1 expressing PC3 and MDA-MB-231 cells 
exhibited significantly reduced growth potential compared 
to wild-type MTSS1 or EV infected cells (Figure 6A-
6D). Consistent with this finding, ectopic expression of 
S322A-MTSS1 exerted stronger ability than WT-MTSS1 
or EV controls in decreasing cell entry into the S phase, 
Figure 7: Mutant MTSS1 inhibits PC3 and MDA-MB-231 cancer cells migration. (A-D) PC3 (A) or MDA-MB-231 (C) cells 
were infected with pBabe-EV, pBabe-HA-wild-type-MTSS1 or pBabe-HA-S322A-MTSS1 retroviral vectors and after 3 days of puromycin 
(1 µg/ml) selection to eliminate the non-infected cells, the generated various cell lines were subjected to trans-well cell migration assay and 
photographed. Quantitative measurement of migrated PC3 (B) or MDA-MB-231 (D) cells was assessed after 12 hours. The number of cells 
was normalized against the number of cells in the corresponding pBabe-EV cells. The error bars represent mean ± SD (n = 3) * p< 0.05  (n= 
3). (E-F) Scratch assays were performed with PC3 cells that were infected with pBabe-EV, pBabe-HA-wild-type-MTSS1 or pBabe-HA-
S322A-MTSS1 retroviral vectors followed by 3 days of puromycin (1 µg/ml) selection to eliminate the non-infected cells. The generated 
various PC3 cell lines were seeded on a 6 well plate and scratched on the surface with a 200 μl pipette tip. Relative values were set at 1 
of the gap width at the time of the scratch. Representative photographs at time points 0 and 18 hours after the scratch (E). Measurements 
were done in duplicate in 3 separate experiments, and data were depicted as average gap width (F). The error bars represent mean ± SD (n 
= 3). ***p<0.001; *p<0.05. (G-H) Scratch assays were performed with MDA-MB-231 cells that were infected with pBabe-EV, pBabe-HA-
wild-type-MTSS1 or pBabe-HA-S322A-MTSS1 retroviral vectors followed by 3 days of puromycin (1 µg/ml) selection to eliminate the 
non-infected cells. The generated various MDA-MB-231 cell lines were seeded on a 6 well plate and scratched on the surface with a 200 
μl pipette tip. Relative values were set at 1 of the gap width at the time of the scratch. Representative photographs at time points 0 and 18 
hours after the scratch (G). Measurements were done in duplicate in 3 separate experiments, and data were depicted as average gap width 
(H). The error bars represent mean ± SD (n = 3).  ***p<0.001; *p<0.05.Oncotarget 2013; 4: 2348 www.impactjournals.com/oncotarget
as illustrated by reduced BrdU staining in both PC3 and 
MDA-MB-231 cells (Figure 6E-6H). This suggests that 
elevated  MTSS1  expression,  in  part  due  to  deficient 
destruction by the SCFβ-TRCP E3 ligase, might suppress 
tumorigenesis by reducing S phase entry and cellular 
proliferation. 
Furthermore, given the well-characterized role 
of MTSS1 in both cell cytoskeleton remodeling and 
cellular migration, we conducted cell migration assays 
to investigate how SCFβ-TRCP–mediated  destruction  of 
MTSS1 might affect cellular migration, an important 
feature of human cancer invasion and metastasis.   
Notably, compared to wild-type MTSS1 and empty vector 
expressing cells, S322A-MTSS1 expressing prostate 
(PC3) and breast (MDA-MB-231) cancer cells exhibited a 
significant reduction in cell migration (Figure 7A-7D) and 
subsequently, reduced ability in recovering from scarring 
(Figure 7E-7H).  Importantly, these results coherently 
suggest that non-degradable MTSS1 expressing cancer 
cells exhibit more dramatic effects in inhibiting growth 
and  migration  compared  to  wild-type  MTSS1  or  EV-
expressing cells, advocating a critical role of SCFβ-TRCP–
mediated destruction of MTSS1 in suppressing tumor 
growth and migration (Figure 8).  
DISCUSSION
Downregulation of MTSS1 has been observed 
in many types of human cancers, and complete loss of 
MTSS1 is associated with poorly differentiated metastatic 
tumors, and with poor survival rate [6-9]. However, 
the underlying molecular mechanisms responsible for 
reduced expression of MTSS1 in human cancers remain 
largely  unknown. To  this  end,  our  study,  for  the  first 
time, identified the β-TRCP/CKIδ signaling as a major 
regulatory mechanism that governs MTSS1 degradation.   
β-TRCP  is  an  F-box  protein,  which  regulates  many 
cellular processes by the timely targeting of various 
substrates for proteasome-mediated degradation [36]. 
However,  the  exact  role  of  β-TRCP  in  tumorigenesis 
could be tissue specific or cellular context-dependent. 
β-TRCP dysfunction, including both loss of β-TRCP and 
elevated expression of β-TRCP, have been reported in 
distinct types of human cancers [22]. Notably, β-TRCP 
overexpression has been reported in certain tumor types 
including human breast or prostate cancers, which could 
lead to increased degradation of its substrates [24, 37]. Our 
study suggests that at least in the breast or prostate cancer 
settings, β-TRCP overexpression could possibly lead to 
increased degradation of the tumor suppressor MTSS1, 
thereby contributing to tumorigenesis. In this direction, 
we found a possible inverse relationship between MTSS1 
and β-TRCP expression in both prostate and breast cancer 
cell lines (Figure 5A). Our study also demonstrated that 
β-TRCP specifically interacts with MTSS1 in a CKIδ-
dependent manner, and further promotes the ubiquitination 
and subsequently proteasome-mediated degradation of 
MTSS1 (Figure 4B). Although previous reports indicate 
that dysregulation in MTSS1 gene expression in part 
contributes to loss of MTSS1 [8], our study indicates the 
accelerated MTSS1 degradation, possibly due to elevated 
expression of β-TRCP, could be an alternative mechanism 
accounting for reduced abundance of the MTSS1 tumor 
suppressor in various human cancers.  
In  this  study,  we  also  identified  CKIδ  as  the 
upstream kinase that is potentially involved in β-TRCP-
mediated degradation of MTSS1. We found that CKIδ, 
but not other CKI isoforms, phosphorylates MTSS1 at 
Figure 8. Proposed model for how aberrant elevation of SCFβ-TRCP-mediated ubiquitination and degradation of the MTSS1 tumor suppressor 
may contribute to tumorigenesis and metastasis in part by promoting tumor cell growth and migration.Oncotarget 2013; 4: 2349 www.impactjournals.com/oncotarget
Ser322 within the DSGXXS phosphodegron to trigger its 
interaction with β-TRCP for subsequent ubiquitination 
and degradation of MTSS1. Consistently, wild-type, 
but not a S322A mutant form of MTSS1 interacted with 
β-TRCP. As  a  result,  S322A-MTSS1  was  resistant  to 
β-TRCP/CKIδ-mediated degradation, thereby displaying 
extended half-life. These findings support a critical role for 
phosphorylation of Ser322 in regulating MTSS1 stability. 
However, it remains to be determined whether in addition 
to elevated β-TRCP expression [24, 37, 38], cancer cells 
also exhibit increased CKI activity, resulting in increased 
degradation of MTSS1. Notably, it has been demonstrated 
that  aberrant  CKI  activity  is  linked  to  carcinogenesis 
[39].  More specifically, the CKIδ and CKIε isoforms 
have been known to possess growth promoting and anti-
apoptotic characteristics, and elevated CKIδ and CKIε 
activities are associated with the development of ductal 
carcinoma of the pancreas [40]. Moreover, increased CKI 
activity promotes SV40-induced cellular transformation 
both in vitro and in vivo, suggesting a potential oncogenic 
role of CKI in tumorigenesis [41]. Taken together, these 
observations indicate that aberrancies in the MTSS1 
degradation pathway, either by elevated expression of 
β-TRCP,  or  hyper-activation  of  CKIδ,  may  possibly 
downregulate the MTSS1 tumor suppressor to facilitate 
tumor cell growth and cancer progression (Figure 8).
Consistent with this notion, we found that compared 
to  cells  expressing  either  WT-MTSS1  or  EV  control, 
ectopic expression of non-degradable MTSS1 (S322A) 
significantly  reduced  cell  growth  and  S  phase  entry 
as evidenced by decreased BrdU staining, as well as 
markedly halted cellular migration ability. These findings 
indicate that MTSS1 expression could prevent cancer cell 
growth, migration and possibly invasion. Although the 
precise molecular mechanisms by which MTSS1 inhibits 
tumor growth and metastasis remain largely unknown, it 
was reported that MTSS1 levels inversely correlate with 
the growth, invasion, adhesion and migration of kidney 
cancer cells, and MTSS1 suppresses kidney cancer cell 
migration via the Sonic hedgehog (SHH) pathway [9]. 
Other studies have indicated that MTSS1 promotes 
cell-cell junction assembly through recruiting the small 
GTPase and actin, which drives junction maintenance. 
Therefore, loss of MTSS1 in cancers may lead to the loss 
of junction stability, which ultimately promotes EMT 
and metastasis [42]. Furthermore, MTSS1 is known to 
negatively regulate the epidermal growth factor signaling 
to suppress metastasis [43]. Further studies are required 
to reveal the exact molecular mechanisms and signaling 
pathways through which MTSS1 modulates cancer cell 
migration and invasion.
In summary, our study provides a possible novel 
molecular mechanism for the frequent reduction in 
expression of the MTSS1 tumor suppressor in various 
types of human cancers. Our work further suggest that 
in part by restoring MTSS1 expression to suppress 
cancer cell growth, proliferation and metastasis, β-TRCP 
inhibitors or CKI inhibitors may be beneficial in treating 
various types of human cancers, particularly the metastatic 
cancers that are associated with poor survival rates. 
MATERIAL METHODS
Cell Culture:
HeLa, 293T, 293FT cells and the breast cancer cell 
lines MCF-7 and MDA-MB-231 were cultured in DMEM 
medium (Life Technologies, CA) supplemented with 10% 
FBS, penicillin and streptomycin.  The prostate cancer 
cell lines DU145 and PC3 were cultured in RPMI 1640 
medium with 10% FBS and antibiotics.  
Plasmids:
MTSS1 cDNAs were subcloned using the Pfu 
polymerase (Agilent Technologies) into the pCMV-GST 
[34] or the pCDNA3-Myc vector to create GST-MTSS1 
or Myc-MTSS1 in frame fusion protein, respectively. 
Short hairpin RNAs (shRNA lentivirus vectors), i.e., 
shRNA–β-TRCP1,  shRNA–β-TRCP1+2,  shRNA-GFP, 
and CKI constructs were described previously [32, 44]. 
Flag–β-TRCP1  and  Flag–β-TRCP1-R474A  constructs 
were described previously [30, 34]. Myc-Cullin 1, 
Myc-Cullin 2, Myc-Cullin 3, Myc-Cullin 4A, and Myc-
Cullin 5 constructs were gifts from J. DeCaprio (Dana-
Farber Cancer Institute, Boston, MA). Lentiviral shRNA 
constructs against GFP and CKIδ were obtained from 
W. Hahn (Dana-Farber Cancer Institute, Boston, MA). 
shRNA lentiviral vectors against Cullin 1 and Cullin 4A 
were gifts from J. Wade Harper (Harvard Medical School, 
Boston, MA).
Cell  transfection  and  viral  transduction 
procedures:
For cell transfection, 5 × 105 HeLa or 293T cells 
were seeded in 60-mm plates and transfected using 
Lipofectamine  (Invitrogen)  in  OptiMEM  medium 
(Invitrogen) for 48 hours according to the manufacturer’s 
instructions. For viral transduction experiments, 6 × 
105  HEK  293T  cells  were  seeded  in  60-mm  dishes 
and cotransfected the next day with each lentivirus or 
retrovirus vector, along with helper plasmids (i.e., gag-
pol and VSV-G were used for lentiviral infections). Media 
with progeny virus from transfected cells was collected 
every 24 h for 2 d, and then filtered with 0.45-µm filters 
(Millipore) and freshly used to infect 293T, HeLa, prostate 
or breast cancer cells overnight in the presence of 8 µg/ml 
Polybrene (Sigma-Aldrich). After infection, the cells were Oncotarget 2013; 4: 2350 www.impactjournals.com/oncotarget
selected with 1 µg/ml puromycin (Sigma-Aldrich) for 72 
hours to eliminate the uninfected cells before collecting 
the  whole  cell  lysates  (WCLs)  for  the  subsequent 
biochemical assays. Knockdown or overexpression in the 
transduced cells was confirmed by real-time RT-PCR or 
western blot analysis. 
Antibodies and reagents:
Anti-MTSS1 antibody (4386) was purchased 
from Cell Signaling Technology. α-c-Myc (9E10) and 
polyclonal α-HA antibodies (Y-11) were purchased from 
Santa Cruz Biotechnology. α-Tubulin antibody (T-5168), 
α-Vinculin antibody (V-4505), polyclonal α-Flag antibody 
(F-2425), monoclonal α-Flag antibody (F-3165), α-HA 
agarose beads (A-2095), peroxidase-conjugated α-mouse 
secondary antibody (A-4416) and peroxidase-conjugated 
α-rabbit secondary antibody (A-4914) were purchased 
from Sigma. Monoclonal α-HA antibody (MMS-101P) 
was  purchased  from  Covance  and  α-GFP  antibody 
(632380) was from Invitrogen. Anti-Cullin 1 (4995) and 
anti–β-TRCP1 (4394) antibodies were purchased from 
Cell Signaling Technology. 
Immunoblots and immunoprecipitation:
Cells were lysed in EBC-lysis buffer (50 mM Tris, 
pH 8.0, 120 mM NaCl, and 0.5% NP-40) supplemented 
with protease inhibitors (Complete Mini; Roche) and 
phosphatase inhibitors (phosphatase inhibitor cocktail set I 
and II; EMD Millipore). The protein concentrations of the 
lysates were measured using a protein assay reagent (Bio-
Rad Laboratories, CA) on a DU-800 spectrophotometer 
(Beckman Coulter). The lysate samples were then resolved 
by SDS-PAGE and immunoblotted with the indicated 
antibodies. For immunoprecipitation assays, 20 hrs of 
post transfection, cells were treated with 10 µM MG132 
overnight before harvesting for immunoprecipitation. 800 
µg of protein lysates were incubated with the appropriate 
antibodies (1–2 µg) overnight at 4°C, followed by addition 
of carrier beads. Immunocomplexes were washed five 
times with NETN buffer (20 mM Tris, pH 8.0, 100 mM 
NaCl,  1  mM  EDTA,  and  0.5%  NP-40)  before  being 
resolved by SDS-PAGE and immunoblotted with indicated 
antibodies.
Protein degradation analysis and protein half-life 
studies:
Cells were seeded in 6-cm culture dishes 20 hrs 
before transfection. Cells were transfected with 2.0 µg 
Myc-MTSS1, along with 1.0 µg Flag-β-TRCP1 and 0.1 
µg of a plasmid encoding GFP as an internal control, in 
the presence or absence of 0.4 µg Myc-CKIδ. For half-life 
studies, 20 µg/ml cycloheximide (CHX; Sigma-Aldrich) 
was added to the medium 40 hrs of post transfection. At 
various time points thereafter, cells were lysed and protein 
concentrations were measured. 30 µg of the indicated 
whole cell lysates (WCL) were separated by SDS-PAGE 
and protein levels were measured by immunoblot analysis.
In vivo ubiquitination assay:
Cells were transfected with His-Ubiquitin along with 
Myc-MTSS1 (wild-type or S322A) and Flag-β-TRCP1. 
Thirty-six hours after transfection, cells were harvested, 
and the lysates were incubated with Ni-NTA matrices 
(Qiagen) at 4 °C for 12 h in the presence of 8 M Urea pH 
7.5. Immobilized proteins were washed five times with 8 
M Urea pH 6.3 before being resolved by SDS-PAGE and 
immunoblotted with the anti-Myc antibody [45].
Scratch assay:
Cancer cells were grown to confluency in a 6-wells 
plate. The cell monolayer was scraped in a straight line 
with a tip. Photographs of the scratch were taken at 0 h 
and 18 h. Gap width at 0 h was set to 1. Gap width analysis 
was performed with PhotoshopCS4 using the analytical 
ruler tool. Measurements were taken at multiple defined 
sites (＞5) along the scratch. Each scratch was given an 
average of all measurements. Data are expressed as the 
average of three independent experiments.
Cell migration assay:
For cell migration assay, 1 × 105 cells in serum-
free media containing 0.1% BSA were added to the upper 
chamber of a Transwell Filter (8 μm pore size; Corning) in 
triplicates. Cell-conditioned media was added to the lower 
chamber. After a 16-h incubation at 37 °C, non-migrated 
cells at the top of the filter were removed using cotton 
swabs. Cells that had migrated to the bottom of the filter 
were fixed and stained using the Hema-3 stain set.  Cells 
were then counted using a 20× objective, and four fields 
were chosen per well with three wells per each condition 
[29].
Bromodeoxyuridine (BrdU) labeling:
BrdU labeling was performed as described 
previously [46]. Briefly, cultures were incubated with 1 
μg/ml (3 µM) BrdU and 1 mg/ml uridine for 48 h. Cells 
were  washed  with  PBS,  fixed  with  ice-cold  absolute 
methanol for 10 min, treated with 1.5 M HCl for 1 h at 
room temperature, and neutralized with 0.1 M borate 
buffer (pH 8.5) for 30 min. After blocking with 0.1% 
bovine serum albumin (BSA) in PBS for 30 min at 37°C, Oncotarget 2013; 4: 2351 www.impactjournals.com/oncotarget
cells were incubated with 5 µg/ml anti-BrdU monoclonal 
antibody (PharMingen) in 0.1% BSA/PBS for 1 h, washed 
with 0.1% BSA/PBS, and incubated with 1 μg/ml HRP-
conjugated rabbit anti-mouse secondary antibody (Jackson 
Immunoresearch) for 1 h. Cells were then washed 
extensively with ammonia-buffered phosphate (ABP; 
0.1 M NaH2PO4 brought to pH 7.0 with ammonium 
hydroxide) and stained for 12–16 h at room temperature 
with 1.3 mM 3,3-diaminobenzidine in ABP containing 
0.004% H2O2. The experiments were performed 3 times 
to generate error bars.
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